BioSpace News Archive

Deployment of Microtox® PD and Microtox® BT Novel Sensors for identification of pathogenic viruses including SARS-CoV-2

Isofol Medical AB, provided an update on the extension study portion of the ISO-CC-005 Phase I/IIa study.

During September, Calliditas Therapeutics AB has allotted 111,250 common shares within the company’s warrant program issued in 2017.

LOI to acquire Isolate Lab which will increase internal production of up to 150 kilograms per month of 99.9% pure isolate

SentiAR, a pioneer in visualization technologies for surgical applications announces U.S. Food and Drug Administration 510 clearance of its groundbreaking CommandEP™ system, the first holographic guidance system to be used during an invasive cardiac procedure.

Iterum Therapeutics plc announced that, based on discussions at a pre-NDA meeting with the U.S. Food and Drug Administration, it plans to proceed with an NDA submission for sulopenem etzadroxil/probenecid, a bilayer tablet, for the treatment of uncomplicated urinary tract infections in patients with a quinolone-resistant pathogen.

IGM Biosciences, Inc. announced that the first patient has been dosed in its Phase 1 clinical trial evaluating IGM-8444, an IgM antibody targeting the Death Receptor 5 protein, in patients with solid cancers and non-Hodgkin’s lymphoma.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that the first patient has been dosed in its first-in-human Phase 1 open-label, multicenter, dose-escalation study of PRT1419 in patients with relapsed/refractory hematologic malignancies.

Bio-Techne Corporation announced the grand opening of its approximately 61,000 square foot state-of-the-art GMP manufacturing facility.

Biotech maven joins early-stage cancer detection company utilizing innovative microbiome analysis